查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1917752

早產和胎膜早破 (PROM) 檢測市場 - 2026-2031 年預測

Preterm Birth and PROM Testing Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計早產和胎膜早破 (PROM) 檢測市場將從 2025 年的 17.48 億美元成長到 2031 年的 25.21 億美元，複合年成長率為 6.3%。

受全球早產和胎膜早破（PROM）病例數量不斷增加的推動，早產和胎膜早破（PROM）檢測市場需求日益成長。這些診斷工具能夠在早期發現孕婦胎膜破裂，從而及時干預，減少併發症，並有可能預防早產。

主要成長要素是由於不健康的生活方式和壓力等因素導致早產發生率上升。此外，青少年懷孕率的上升以及孕婦妊娠毒血症病例的增加也預計將對市場擴張產生正面影響。妊娠毒血症併發症每年都會顯著增加孕產婦和胎兒的死亡風險，而青少年母親早產及相關新生兒疾病的風險更高。

早產帶來的不良健康後果凸顯了早期發現的必要性。早產兒容易出現許多短期和長期併發症，包括呼吸窘迫症候群、心血管疾病、顱內出血、壞死性小腸結腸炎、貧血、黃疸、低血糖、腦性麻痹、發育遲緩、感染疾病和氣喘等慢性疾病。

政府措施和正在進行的臨床研究計劃正在推動市場發展。世界衛生組織等機構正在進行研究，以改善中低收入國家孕婦和早產兒的護理，包括產前皮質類固醇、營養管理和袋鼠即時護理等方面的試驗。國際婦產科聯合會等合作組織正在為早產兒的管理提供良好實踐建議。

從區域來看，由於技術進步、意識提高以及Hologic、Abbott Laboratories和Sera Prognostics Inc.等主要企業的存在，北美預計將佔據主要市場佔有率，並在預測期內實現顯著成長，這些參與者正在推動更多機會和創新。

該領域的主要企業包括Hologic公司，這是一家專注於女性健康的跨國公司。該公司提供周產期檢測解決方案，例如用於評估早產風險的Rapid fFN®檢測，以及QuikCheck fFN®和Rapid fFN® 10Q Cassette Kit等試劑盒。 2023年2月，另一家知名的女性健康相關企業Sera Prognostics Inc.宣布了在ChristianaCare進行的AVERT早產試驗的積極初步結果，該試驗表明新生兒發病率和死亡率有所降低。

這些臨床、人口統計和支持性因素正在推動市場整體快速擴張，透過提高診斷能力來滿足母胎醫學的關鍵需求。

本報告的主要優勢：

  • 深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略進入市場的可能性。
  • 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用這些見解，在快速變化的環境中製定策略決策，發展新的商業機會和收入來源。
  • 受眾廣泛：對Start-Ups、研究機構、顧問公司、中小企業和大型企業都很有用且經濟實惠。

以下是一些公司如何使用這份報告的範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

  • 2021年至2025年的實際數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區（包括國家）分類的收入和預測評估
  • 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

5. 早產和胎膜早破 (PROM) 檢測市場（按早產檢測機構分類）

  • 介紹
  • 骨盆腔檢查
  • 超音波
  • 其他

6. 早產和胎膜早破 (PROM) 檢測市場（按 PROM 檢測分類）

  • 介紹
  • 硝嗪試驗
  • 蕨狀結晶試驗
  • 其他

7. 按最終用戶分類的早產和胎膜早破 (PROM) 檢測市場

  • 介紹
  • 診斷檢查室
  • 醫院
  • 其他

8. 各地區早產及胎膜早破 (PROM) 檢測市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Hologic, Inc
  • Abbott
  • Sera Prognostics Inc.
  • CooperSurgical Inc.
  • IQ Products
  • Qiagen NV
  • BHR Pharmaceuticals
  • NX Prenatal, Inc.

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615710

The preterm birth and PROM testing market, with a 6.3% CAGR, is expected to grow to USD 2.521 billion in 2031 from USD 1.748 billion in 2025.

The preterm birth and PROM testing market is experiencing rising demand driven by increasing global cases of preterm births and premature rupture of membranes (PROM). These diagnostic tools enable early detection of fetal membrane rupture in pregnant women, facilitating timely interventions to mitigate complications and potentially prevent preterm delivery.

Key growth drivers include escalating preterm birth incidences influenced by factors such as unhealthy lifestyles and stress. Additionally, rising adolescent pregnancies and preeclampsia cases among pregnant women are expected to positively influence market expansion. Preeclampsia complications contribute to significant maternal and fetal mortality annually, while adolescent mothers face elevated risks of preterm delivery and associated neonatal conditions.

The adverse health effects of preterm birth underscore the need for early detection. Preterm births are associated with numerous short- and long-term complications, including respiratory distress, cardiovascular issues, intracranial hemorrhage, necrotizing enterocolitis, anemia, jaundice, hypoglycemia, cerebral palsy, developmental delays, and chronic conditions such as infections and asthma.

Government initiatives and ongoing clinical research projects support market advancement. Organizations like the WHO conduct studies in low- and middle-income countries to enhance care for pregnant women and preterm infants, including trials on antenatal corticosteroids, nutritional management, and immediate kangaroo mother care. Collaborative efforts, such as those from the International Federation of Gynecology and Obstetrics, provide good practice recommendations for preterm birth management.

Geographically, North America is poised for significant growth, holding a substantial market share during the forecast period. Contributing factors include technological advancements, heightened awareness, and the presence of major industry players such as Hologic, Abbott Laboratories, and Sera Prognostics Inc., which enhance accessibility and innovation.

Leading companies in the sector include Hologic Inc., a multinational focused on women's health, offering perinatal testing solutions like the Rapid fFN(R) test to assess preterm birth risk, along with kits such as QuikCheck fFN(R) and Rapid fFN(R) 10Q Cassette Kit. Sera Prognostics Inc., a prominent women's health company, reported positive top-line results in February 2023 from the AVERT Preterm Trial, demonstrating reductions in neonatal morbidity or death when conducted at ChristianaCare.

Overall, the market is expanding rapidly due to these clinical, demographic, and supportive factors, addressing critical needs in maternal-fetal medicine through improved diagnostic capabilities.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Preterm Birth and PROM Testing Market Segmentation

  • By Preterm Birth Tests
  • Pelvic Exam
  • Ultrasound
  • Others
  • By PROM Tests
  • Nitrazine Test
  • Ferning Test
  • Others
  • By End-User
  • Diagnostic Laboratories
  • Hospitals
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PRETERM BIRTH AND PROM TESTING MARKET BY PRETERM BIRTH TESTS

  • 5.1. Introduction
  • 5.2. Pelvic exam
  • 5.3. Ultrasound
  • 5.4. Others

6. PRETERM BIRTH AND PROM TESTING MARKET BY PROM TESTS

  • 6.1. Introduction
  • 6.2. Nitrazine Test
  • 6.3. Ferning Test
  • 6.4. Others

7. PRETERM BIRTH AND PROM TESTING MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Others

8. PRETERM BIRTH AND PROM TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Hologic, Inc
  • 10.2. Abbott
  • 10.3. Sera Prognostics Inc.
  • 10.4. CooperSurgical Inc.
  • 10.5. IQ Products
  • 10.6. Qiagen N.V.
  • 10.7. BHR Pharmaceuticals
  • 10.8. NX Prenatal, Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations